On 8 September 2026, Hebei Haiwei Electronic New Material Technology Co., Ltd. (09609.HK) announced that it had subscribed for 1,154,000 new shares of Sungrow Hydrogen Energy Technology Co., Ltd., a water-electrolysis hydrogen equipment maker and subsidiary of Sungrow Power Supply (300274), for RMB 20 million (approximately 0.2825% of enlarged capital), completed on 28 April 2026; after Sungrow Hydrogen's new financing round on 10 August 2026, its implied post-money valuation reached approximately RMB 7,223 million and the company's stake was diluted to approximately 0.2769%, with the investment not constituting a discloseable transaction.
On 8 September 2026, Tianjin TEDA Biomedical Engineering Company Limited (08189.HK) announced in a voluntary announcement the signing of a strategic cooperation framework agreement with Hunan Xingchen Tongyong Robot Co., Ltd., under which the parties will jointly build embodied intelligence scenario open centres and an innovation and application ecosystem, and promote the industrial application of an integrated healthcare large language model and embodied intelligence technology system.
On 8 September 2026, Tianjin TEDA Biomedical Engineering Company Limited (08189.HK) announced in a voluntary announcement that its controlling subsidiary Yishu Jingcheng had signed a strategic cooperation agreement with the Design Institute under central SOE China Communications Construction Group, to jointly develop and operate projects in public data operation and industry large language models, with Yishu Jingcheng providing full-process data services and the Design Institute contributing top-tier qualifications and large-project integration experience.
On 8 September 2026, MeiG Smart Technology Co., Ltd. (03268.HK) announced that its wholly-owned subsidiary Meige Zhitou, as a limited partner, will subscribe RMB 30 million from its own funds into Suzhou Puhua Chenguang Venture Capital Partnership (Limited Partnership), representing approximately 2.84% of the total subscribed capital of RMB 1.057 billion; the fund focuses on the integrated circuit industry chain with a seven-year term, and the investment does not constitute a connected transaction or major asset restructuring and requires no board or shareholders' approval.
On 8 September 2026, Ascletis Pharma Inc. (01672.HK) announced in a voluntary announcement that it had initiated a US Phase I study of ASC36 oral tablets, an oral amylin receptor agonist peptide, for obesity following FDA IND approval, marking its fourth peptide Phase I study this year; in non-human primates, once-daily dosing for seven days achieved up to 13.2% mean weight loss versus baseline, with steady-state absolute oral bioavailability of 6% to 8%.
On 8 September 2026, Holly Futures Co., Ltd. (03678.HK) announced the proposed appointment of Mr. Liu Xiaoxing as an independent non-executive director to succeed the resigning Mr. Zhang Hongfa; Mr. Liu is currently a professor, doctoral supervisor and head of the finance department at Southeast University's School of Economics and Management, and his appointment is subject to review by the Shenzhen Stock Exchange and approval at an extraordinary general meeting, with an annual fee of HKD 120,000 (after tax).
On 8 September 2026, Minieye Technology Co., Ltd. (02431.HK) announced in a voluntary announcement that chairman, executive director and general manager Dr. Liu Guoqing had purchased a total of 100,000 H shares on the open market at an average price of approximately HKD 2.5272 per share, raising his beneficial holding to 34,683,503 shares (approximately 7.8%), and approximately 17.57% together with his concert parties.
On 8 September 2026, Sino Biopharmaceutical Limited (01177.HK) announced in a voluntary announcement that preclinical data of TQH5528, an oral STAT6 degrader independently developed by subsidiary Chia Tai-Tianqing Pharmaceutical Group, had been presented at ERS 2026, showing picomolar-level STAT6 degradation superior to comparator KT-621, significant STAT6 downregulation after a single dose in non-human primates, and improved airway hyperresponsiveness in a humanised asthma mouse model, with in vivo safety studies ongoing.
On 8 September 2026, CSPC Pharmaceutical Group Limited (01093.HK) announced in a voluntary announcement that its Category 1 innovative chemical drug SYH2083 Eye Drops had received clinical trial approval from the National Medical Products Administration for dry eye disease, with preclinical studies showing significant efficacy in a mouse dry eye model and potential expansion to allergic conjunctivitis and other inflammatory ocular surface diseases.
On 8 September 2026, Shimao Group Holdings Limited (00813.HK) disclosed further details of the winding-up petition against it, with judgment debts from four Mainland court judgments totalling approximately RMB 2,497,885,817 arising from shortfall make-good obligations under financing trust arrangements; the company said the petitioner has obtained secured assets, that it will oppose the petition vigorously and continue settlement discussions, and that there is no material adverse impact on its operations or financial position at this stage.
On 8 September 2026, FOSUN PHARMA (02196.HK) disclosed that its controlling subsidiary has obtained NMPA approval for FXS5626 (a TYK2/JAK1 dual-target inhibitor) to conduct Phase II/III trials in non-segmental vitiligo, with the Group holding exclusive rights in mainland China, Hong Kong and Macao and cumulative R&D investment of approximately RMB 108 million.
On 8 September 2026, Shanghai Electric Group Company Limited (02727.HK) announced progress in its major litigation over RMB 1 billion loans to China Energy Engineering Group Co., Ltd., with the court ruling in Action II that China Energy must pay interest of RMB 32,532,500, compound interest, default interest of RMB 167,305,170.32 accrued to 29 June 2026 and legal fees, with Zhongji Guoneng bearing joint and several liability; the first-instance judgment is not yet effective and the impact on profits remains uncertain.
On 8 September 2026, Jiangsu New Vision Automotive Electronics Co., Ltd. (02632.HK) announced in a voluntary announcement that it had entered the global supply system of a leading international German automaker for the first time and received a project designation for a globally-marketed model to develop and supply HUD (head-up display) products, with mass production planned for 2028.
On 8 September 2026, HKEX censured HOME CONTROL (01747.HK), its former chairman and non-executive director Mr. Gao Yu and former non-executive director Mr. Chen Guojing over the company's use of IPO proceeds to subscribe for investment products after its 2019 listing, failure to disclose the change of proceeds use and failure to announce discloseable transactions in a timely manner; each relevant director must complete 20 hours of compliance training, and the company and the directors have agreed to accept the sanctions.
On 8 September 2026, YANCOAL AUS (03668.HK) announced the issue of 959,151 performance rights at a nil price to senior executives under the 2026 long-term incentive plan, of which 28,012 lapsed immediately due to departures, leaving 931,139 rights outstanding subject to performance-based vesting in December 2028.
On 8 September 2026, REMT (00601.HK) announced the completion of a placing of 96 million new shares at HKD 0.05 each, raising approximately HKD 4.5 million net for professional fees, staff costs and payables; Ming Xin's shareholding was diluted to approximately 34.43%.
